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Background: Genetic testing for risk of weight gain is already available over the internet despite uncertain benefits
and concerns about adverse emotional or behavioral effects. Few studies have assessed the effect of adding
genetic test feedback to weight control advice, even though one of the proposed applications of genetic testing is
to stimulate preventive action. This study will investigate the motivational effect of adding genetic test feedback to
simple weight control advice in a situation where weight gain is relatively common.
Methods/design: First-year university students (n = 800) will be randomized to receive either 1) their personal
genetic test result for a gene (FTO) related to weight gain susceptibility in addition to a leaflet with simple weight
control advice (‘Feedback + Advice’ group, FA), or 2) only the leaflet containing simple weight control advice
(‘Advice Only’ group, AO).
Motivation to avoid weight gain and active use of weight control strategies will be assessed one month after
receipt of the leaflet with or without genetic test feedback. Weight and body fat will be measured at baseline and
eight months follow-up. We will also assess short-term psychological reactions to the genetic test result. In addition,
we will explore interactions between feedback condition and gene test status.
Discussion: We hope to provide a first indication of the clinical utility of weight-related genetic test feedback in
the prevention context.
Trial registration: Current controlled trials ISRCTN91178663
Keywords: Genetic test feedback, Obesity prevention, DNA test, Behavior changeBackground
‘Personalized’ healthcare aims to offer specific, targeted
advice for disease prevention based on genetic risk sta-
tus, [1,2]. Addition of information about genetic risk
markers to standard care has been put forward as a way
of empowering individuals to take responsibility for
health maintenance, thereby maintaining quality of life
and lowering healthcare costs [3]. To date, the clinical
utility of most genetic risk markers is assumed to be low
because of the small effect sizes of genes identified for
‘common’ conditions. However, genetic testing can already
be purchased over the internet without involvement of
healthcare providers (for example, www.23andme.com;
www.deCODEme.com), suggesting that consumers are
interested in this kind of information. The idea that* Correspondence: susanne.meisel.09@ucl.ac.uk
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reproduction in any medium, provided the orgenetic test feedback could promote behavior change is
consistent with psychological theories (such as protection
motivation theory [4]) that identify perceptions of risk as
important for motivating risk-reducing actions. Within
this model, however, a lower-risk genetic test result
might reduce motivation. An alternative perspective is
that ‘genetic determinism’ (the idea that genetic effects
cannot be modified) could lead to a fatalistic attitude
towards health maintenance for example, [5] in the case
of a higher-risk result, whereas a lower-risk result could
induce a false sense of immunity and complacency for
example, [6]. Furthermore, there are concerns that indi-
viduals may discount their genetic result if it does not
match their preconceived ideas about illness develop-
ment [7]. To date, few studies have investigated the
consequences of genetic test feedback for common condi-
tions. One approach uses ‘vignettes’ in which people
imagine receiving a genetic test result and anticipate theirLtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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of weight gain suggest that higher-risk feedback increases
motivation to change behavior and does not appear to
induce fatalism [8-10], while lower-risk feedback does
not appear to induce complacency, and may even have a
mildly motivating effect [9]. However, the gap between
expressed intentions in the vignette context and actual
behavior may be wide, so at best, these results only give
an indication of the effects of actual test feedback.
‘Real’ genetic test feedback has received most attention
in the smoking cessation field following the early discov-
ery of genes coding for enzymes that reduce risk for lung
cancer (GSTM1 and CYP2D6). There has been evidence
of increased motivation to quit following genetic test
feedback [11,12], although a recent Cochrane review of
five clinical studies failed to show any statistically signifi-
cant effects on quitting when incorporating genetic feed-
back results into smoking cessation programs, either in
the short term (two weeks), or in the longer term (six
months) although study heterogeneity limited the inter-
pretation of the results [13]. However, the physiological
and psychological drivers of nicotine addiction make
smoking cessation particularly difficult to achieve, and
quit attempts are marked by frequent relapse [14]. Add-
ing genetic test feedback in this context might be less in-
fluential than for other health promoting behaviors. The
positive feature of these results was that there was no
evidence that smokers receiving lower-risk results
thought of themselves as immune to lung cancer for
example, [12,15]. This corresponds with findings from
vignette studies, and indicates that complacency may
not be a major concern. There is some evidence that in-
clusion of genetic test feedback for risk of obesity into
clinical care may be beneficial. Feedback on a gene
implicated in weight gain (bA3R) resulted in increased
motivation to lose weight in a small sample of obese
individuals [16]. Another small qualitative study giving
feedback on the FTO gene (also linked with weight gain),
found that feedback increased motivation to lose weight
(SFM and JW, unpublished). This study also found that
the ‘scientific’ nature of the gene test result helped over-
weight participants feel less sense of personal failure and
more confidence in managing their ‘condition’. A similar
finding was reported in a community sample of over-
weight and obese adults, where genetic feedback reduced
guilt and self-blame [17]. Raising awareness of the gen-
etic etiology of obesity also helps minimize negative
stereotyping by healthcare professionals [18].
Thus far, most research has centered on the reactions
of already affected individuals, but a key proposed appli-
cation for genetic feedback is prevention of ill health.
The one study in this area analyzed responses to receiv-
ing results from a direct-to-consumer genetic test for a
panel of diseases in over 2000 people who volunteeredto be followed up in return for purchasing their test at a
reduced rate [19]. Neither higher nor lower genetic risk
for the panel of diseases was associated with changes in
anxiety or health behaviors, nor were there changes in
the number of health screening tests although intended
use of health screening increased in the whole group.
However, the participants in the study are likely to have
been ‘early adopters’ of genetic testing who may be more
health conscious than average and have less scope to
change, supported by the fact that most of them were
already following a low-fat diet. It is also possible that
receiving results for a whole panel of diseases has a dif-
ferent effect from receiving results for a single condition
because, inevitably, any high risk results are likely to be
balanced by lower risk for others diseases, which may
generate an overall null effect on risk perception. The
present study will therefore investigate the impact of giv-
ing genetic risk feedback for a single condition, over-
weight, in conjunction with weight control advice, in a
healthy, young adult sample entering a life stage where
risk of weight gain is raised, to discover whether genetic
feedback provides a ‘nudge’ toward unhealthy weight
gain prevention. We will test the effect of adding feed-
back for the FTO gene, which has modest effects on
weight gain and risk of obesity [20], to simple weight
control advice. We use the university context because of
evidence that first-year students have a high risk of
weight gain (sometimes termed the ‘Freshman 15’ or
‘Freshman 5’) and low intentions to implement healthy
behaviors [21,22].
Study objectives and hypotheses
Primary research objective
The primary aim of the study is to test the hypothesis that
adding genetic test feedback to weight gain prevention
advice will result in higher motivation to prevent weight
gain one month after receiving test feedback compared
with receiving weight gain prevention advice alone.
Secondary research objectives
The secondary objectives are to assess differences in ad-
herence to the advice and weight change from baseline
to eight month follow-up in those receiving genetic test
feedback and weight gain prevention advice compared
with advice alone. We hypothesize that participants re-
ceiving genetic test feedback, regardless of risk status,
will be more adherent to the advice and gain less weight
over the study period than those receiving weight gain
prevention advice alone. Within the group of partici-
pants receiving feedback and advice, we will also explore
psychological reactions immediately after receiving gen-
etic test feedback, and interactions between weight sta-
tus and gene test status. We hypothesize that those
receiving a higher-risk genetic test result will show
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to their genetic test result compared to those receiving
an ‘average-risk’ genetic test result. We also predict that
overweight participants receiving a ‘higher-risk’ result
will value having an explanation for their weight more
than normal weight participants, and that overweight par-
ticipants will be more motivated to prevent further weight
gain in response to a higher-risk genetic test result than
those receiving an ‘average-risk’ result. All secondary
objectives are exploratory, because of limited power.
Methods/design
Study design
The design will be an open, two-arm, individually-rando-
mized, controlled trial comparing the effects of genetic
test feedback for risk of weight gain combined with
weight control advice (FA) with a control condition of
giving weight control advice only (AO). The control
group will receive their genetic test result at the end of
the study. A summary of the study procedures is shown
in Figure 1. Participants consenting to take part in the
study will be randomized and offered the following:
Intervention group (‘Feedback and Advice’ group)
Following baseline measurements, participants rando-
mized to the ‘Feedback and Advice’ group will receive
their gene test result in an email, as used by internet-
based genetic testing services. This format was used in a
previous study (SFM and JW, unpublished) and found
acceptable to participants. The result letter will be sent
as an email attachment so that participants can open
and read it at a convenient time. The letter will contain
the personal result in addition to information about
prevalence in the population. The email will also include
a short information leaflet written in simple language,
giving a brief overview about the FTO gene, its mode of
inheritance, and magnitude of influence on body weight.
Contact details of the research team will be included for
questions about the test results. The FTO information
leaflet and the result letter were piloted in a general
population sample that included both men and women
of various ages and ethnicities (n = 35), and has been
used in previous work (SFM and JW, unpublished). Both
were deemed informative, comprehensive and easy to
understand. Readability was assessed with the Flesch
Reading Ease formula and the Flesch-Kincaid Grade
Level formula, and letter and leaflet received a score of
71.0 and 67.0 respectively, which translates to the read-
ing level expected in grade 6 (age 12). Participants will
also receive weight control advice in the form of a short
leaflet containing practical ‘tips’ on how to avoid weight
change when starting university. The format and design
is based on habit formation model [23], and is currently
being evaluated in a large population-based sample [24].Readability of the leaflet was tested with the Flesch
Reading Ease formula and the Flesch-Kincaid Grade
Level formula, and found to be high (71.1), comparable
to the reading level expected in grade 6 (age 12).
Control group (‘Advice Only’ group)
Following baseline measurements, participants rando-
mized to the ‘Advice Only’ control group will receive an
email at the same time as the FA group informing them
that they will receive their test result by the end of the
academic year, resembling a ‘wait-list control’ group for
the gene test feedback condition. The weight control ad-
vice leaflet will be attached to the email, matching the
format of the intervention group. Ethical concerns about
withholding weight control advice from individuals at
increased risk of weight gain, and the likelihood of con-
tamination between groups, led to the decision to send
the leaflet to all participants and therefore not to have a
‘no treatment’ control group that receives neither leaflet
nor genetic feedback. The gene test result will be sent
out in identical format to the intervention group at the
end of the academic year after collection of follow-up
anthropometric data is complete.
Randomization
All consenting participants will be randomized to ‘FA’
(intervention) or ‘AO’ (control) after baseline data collec-
tion is complete and records have been anonymized
using serial numbers. For group allocation, we will use
the randomization function in the Statistical Package
for Social Sciences (SPSS 19 for WindowsW; SPSS Inc.,
Chicago, IL, USA), which randomly assigns a set per-
centage of cases to a specified number of groups. Each
group will consist of 400 participants, and based on
population frequencies of FTO we expect 252 to have at
least one higher-risk (A) allele and 148 to have the
lower-risk (TT) genotype. Randomization will take place
after data collection of each wave is complete, but before
the DNA analyses are conducted. Experimenter bias is
unlikely, as records are anonymous and not easily identi-
fiable. Although neither researchers nor participants will
be blind to group allocation, follow-up weights will be
measured objectively and print-out records kept, which
excludes inadvertent manipulation of records. Question-
naire data will be collected online, which minimizes the
risk of missing data or inadvertent manipulation.
Minimizing other sources of bias
Participants who will select themselves into the study
are likely to be more positive towards genetic testing
than the average student population. However, if genetic
testing were offered through a healthcare provider or
over the internet, the same situation would hold; that is,
only interested individuals would choose to take part,
First year university students invited to take part 
(N = 22 000)    
Eight hundred consent (Response rate: 3.6%). 
Questionnaire assessing motivation to
prevent weight gain (primary outcome)
Allocated to receive genetic test feedback and 
advice (n=400) 
Expected genotype frequencies:  
higher-risk= 252, non-risk=148 
Asked to complete questionnaire to assess 
psychological reactions immediately after 
receiving test feedback
Allocated to receive Advice only (n=400) 
higher-risk= 252, non-risk=148 
Informed they will receive results in 8 
months
Questionnaire assessing motivation to
prevent weight gain (primary outcome)
Allocation
Follow-up 1
(One month)
Randomized (N= 800) 
Enrollment
Follow-up 2
(Eight months)
Re-weigh
Debrief, reimbursement
Re-weigh,
Provide genetic test feedback
Questionnaire to assess psychological
reactions immediately after receiving
feedback
Debrief, reimbursement
Expected genotype frequencies:
Figure 1 Flowchart of study procedures.
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the generalizability of the results.
Recruitment and consent
Ethical approval was granted by the University College
London Research Ethics Committee for non-NHS re-
search in September 2010. Participants will be recruited
at the beginning of two consecutive academic years. Po-
tential participants will be recruited through emails sent
to all first year students (approximately 22,000) enrolled
at University College London (UCL) inviting them to
take part in a study where they will receive information
on their personal genetic risk for weight gain susceptibil-
ity. A ‘collection station’ will be set up at UCL in the first
two weeks of term where participants can receivedetailed information about the study, check eligibility,
enroll, and give saliva for DNA analysis. To ensure that
participants are aware of the details of the study, infor-
mation contained in the information sheet will be reiter-
ated by a researcher. Participants will be told that the
DNA analysis is only for one gene (FTO) which is
related to a small increase in weight gain susceptibility
and that students will be randomly allocated to receive
their results either during term 2 (intervention group) or
at the end of the academic year (control group). Partici-
pants will be informed that their samples will be
destroyed on completion of the study and not stored for
further analyses. Written consent will be obtained before
participants give saliva for DNA analysis. The right to
withdraw from the study without giving reason will be
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destroyed immediately after participant withdrawal.
Participants
Participants will be a volunteer sample (n = 800) of first
year university students.
Inclusion and exclusion criteria
We will include all interested first-year students between
18 and 25 years who are able to give informed consent.
We chose this age range because the association be-
tween FTO and BMI has been found to peak in early
adulthood, with less effect thereafter [25]. As FTO has
been found to have effects in all major ethnic groups, we
will not exclude participants based on ethnicity. We an-
ticipate that a small number of individuals suffering
from eating disorders may express interest in taking
part, because eating disorders are relatively common in
this age group [26]. However, participants have the op-
tion of declining to see weight and body composition
results. If they opt to receive their body composition as-
sessment, they will get brief, personal feedback with it.
We will be careful to avoid discriminating against any-
one based on their weight (high or low) because this
may impair help seeking. Instead, we will offer brief,
general advice on available resources to all participants,
so that those who wish to find help can do so. If a par-
ticipant is distressed by the result, the principal investi-
gator, who is a clinical psychologist, will be available for
intervention. Results from earlier qualitative work indi-
cate that gene test feedback may be helpful even for
individuals with a history of eating disorders, and that
provision of information should be sufficient to elimin-
ate the risk of exaggerating tendencies for disordered
eating (SFM and JW, unpublished).
Proposed study duration
The study will run over three university terms (eight
months).
Measures
Baseline
Body composition
Participants will be asked to remove shoes, socks and
heavy items, but stay otherwise fully clothed. Height will
be measured, rounded up to the nearest centimeter,
using the Leicester Height Measure, a standardized in-
strument for determining height. Weight and body fat
will be assessed using the TANITA TBF-300 MA Body
Composition Analyzer (Tanita, Tokyo, Japan). This uses
electrical impedance to assess body fat which compares
well to other measures of body composition such as
whole body magnetic resonance imaging and dual X-ray
absorptiometry [27]. Participants can opt to receive aprintout of the results together with an explanation by
the research team or not.
DNA Collection and genotyping
Participants will be asked to give a saliva sample for
DNA collection by placing some sugar onto their tongue
to stimulate saliva flow and then ‘drooling’ into a plastic
tube to generate 1.5-2 ml of saliva. Samples will be
coded with a unique identifier number so that they are
anonymous but can be linked back to questionnaire
data. DNA will be isolated and extracted from saliva.
Genotyping of FTO rs9939609 will be performed using
TaqMan; details of extraction and analysis methods have
been published elsewhere [28]. Samples will be analyzed
at the Institute of Metabolic Sciences, Cambridge, which
is a certified research laboratory.
Baseline questionnaire
The baseline questionnaire will be sent by email after
anthropometric data and saliva have been collected. It
will include demographic and health-related measures
(age, gender, course of study, year of study, family his-
tory of overweight), and standardized questionnaires
assessing the following: Diet quality will be determined
using the using the DINE, which is a self-report food
frequency questionnaire, commonly used in clinical
practice, assessing dietary fat, fiber and fruit and vege-
table content [29]. Eating behavior will be assessed with
the Dutch Eating Behavior Questionnaire (DEBQ), which
determines tendencies for emotional eating, restraint
eating and external eating [30]. Physical activity will be
assessed with the Recent Physical Activity Questionnaire
(RPAQ), which assesses time and frequency for a range
of physical activities for commute and leisure [31]. Stress
will be determined using the Perceived Stress Scale-4
(PSS-4, [32]. The PSS-4 is a short version of the 20-item
perceived stress scale, with good psychometric proper-
ties [33]. Four items will assess worry about weight gain
[34] and diet self-efficacy [35]. All questionnaires have
sound psychometric properties and are commonly used
in clinical practice.
Follow-up
Primary outcome
The primary outcome is motivation to engage with
weight gain prevention. It will be assessed using a vali-
dated measure of readiness for behavior change [36,37]
adapted to relate to prevention of weight gain. Indivi-
duals will be asked: ‘Please mark with an ‘X’ the state-
ment out of the next four that best describes you’: ‘I am
not trying to control my weight, and I have no intention
of doing so in the next month’; ‘I am not trying to con-
trol my weight, but I am thinking of doing something in
the next month’; ‘I started to try to control my weight
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my weight for more than a month’. Responses will be
used to classify individuals into one of the five stages of
behavior change outlined by Prochaska and DiClemente
[38]. Participants will also be asked to rate their agree-
ment with one statement each relating to motivation to
prevent weight gain, perceived ease of weight control,
and the priority they are giving to weight control (ran-
ging from ‘never’ to ‘always’). The primary outcome will
be measured one month after the intervention group
receives their genetic test result. We chose the respective
time frame, because we saw it as crucial that participants
would have had sufficient time to think about their re-
sult, to ask any questions, and to implement eventual
behavior change. We will exclude participants who con-
trolled their weight for more than one month, because
the intervention will not be applicable to them.Secondary outcomes
Secondary outcomes are psychological reactions to gen-
etic test feedback and actual behavior change as assessed
by adherence to the individual weight control tips in the
leaflet. Immediately after receiving genetic feedback (FA
group after allocation, AO group after 8 months, see
Figure 1), participants will complete a questionnaire
concerning their psychological reactions using 18 items
adapted from the vignette study by Meisel et al. [9]. One
example is ‘Knowing my FTO gene test result provides
me with an explanation for my body weight’ (strongly
disagree to strongly agree).Adherence to the weight loss tips
Adherence to the weight loss tips will be assessed by
asking: ‘How often in the last month did you. . . (watch
portion sizes, avoid second helpings, slow down your
eating, avoid eating mindlessly/focus on your food, pass
up extra snacks between meals, avoid sweet drinks or
chose a lite drink, integrated some physical activity into
your day)’. Response options were given on a Likert
scale, ranging from ‘never’ to ‘always’.Body composition
Follow-up anthropometric measurements will be col-
lected at eight-month follow-up as at baseline.Comprehension of the genetic test result
Immediately after receiving their genetic test feedback,
participants will be asked what their genetic test result
was (AA, AT, TT, I don’t know), and whether their test
result puts them ‘at lower/average/higher risk for gaining
weight’, also including the option ‘don’t remember’ to as-
sess comprehension of the test result.Minimizing drop out
We anticipate about half the participants not returning
for follow-up measures because attrition rates of this
magnitude have been reported from other longitudinal
studies with students for example, [39,40]. To minimize
attrition, we will send several email reminders; this has
been shown to increase follow-up rates [41]. We will
also offer a modest incentive (£5 voucher) to everyone
who fills out the follow-up questionnaire and returns for
the final weighing session. We feel that this is justified
by the time and effort participants spend taking part in
the study.
Sample size and assumptions
A power calculation conducted a priori using GPower (ver-
sion 3.1; http://www.psycho.uni-duesseldorf.de/abteilungen/
aap/gpower3/download-and-register) showed that a total
sample size of n = 340 should suffice to detect a small effect
(η = 0.25) for motivation to prevent weight gain between
‘Feedback and Advice’ and ‘Advice Only’ group with 95%
power or greater at the 5% significance level, accounting for
an attrition rate of 60% (based on research with other student
samples). We chose the small effect size based on data from
the vignette study [9] and on FTOs moderate effects on
weight.
Statistical analyses
Differences between completers and non-completers of
follow-up will be assessed with chi-square tests for cat-
egorical variables and independent-samples t-tests for
continuous variables. Participants who had been control-
ling their weight for more than one month will be
excluded from analysis, because the intervention will not
be applicable. Correct recall of the test result will be
assessed with a chi-square test. Associations between
genotype status and correct recall will be assessed with a
one-way ANCOVA, including age, gender and body
mass index (BMI) as covariates, as recall may affect sub-
sequent reactions.
Primary
Ordinal logistic regression will be used to assess the dif-
ference in ‘Feedback and Advice’ versus ‘Advice Only’
group for motivation to prevent weight gain. Additional
predictor variables will include age, gender and weight
status at baseline, because these may influence results.
Secondary
Results from all secondary analyses will be considered as
exploratory. One-way ANOVAs, followed by one-way
ANCOVAs will be used to examine immediate psycho-
logical reactions to genetic test feedback in the sample
overall once the AO group participants have received
their genetic test results. Repeated-measures ANOVAs
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measures within groups over time in the sample overall.
Anthropometric differences between groups will be
determined using one-way ANCOVA. Age, gender and
baseline BMI will be included as covariates. Changes in
diet quality, eating behavior and physical activity in the
sample overall will be examined with repeated-measures
ANOVAs. Changes between groups will be examined
using one-way ANCOVAs, including age, gender and
baseline BMI as covariates. Group differences in actual
behavior change (as measured by adherence to the indi-
vidual tips) will be assessed with a one-way ANCOVA.
In addition, we will build an additive score of the total
number of tips adhered to at least ‘occasionally’ and
compare this in intervention and control group with a
one-way ANCOVA. Age, gender and baseline BMI will
be included as covariates. Bonferroni corrections will be
used for multiple comparisons in all analyses. Within
the ‘Feedback and Advice’ group, FTO status will be
dichotomized into high/average risk, with those having
at least one risk allele being classified as ‘higher-risk’.
Ordinal regression analyses will be used to examine
effects of risk status on motivation to control weight, as
well as interactions between risk status and baseline
BMI. Age and gender will also be included as predictor
variables in the model. Finally, we will assess predictors
of motivation to control weight with a multinomial re-
gression analysis. We will include all potential predic-
tors, including age, gender, FTO status, as well as stress,
eating behavior, baseline BMI, and weight satisfaction.
Discussion
The disappointing results from most trials of weight gain
prevention warrant development of novel methods to
engage individuals with weight control. Genetic test
feedback has the potential to be a tool that could help
raise awareness of susceptibility to weight gain. The in-
creasing popularity of genetic testing to ‘personalize’
medicine makes evaluation of its effects imperative. The
current trial uses a rigorous study design, taking ethical
and practical concerns into consideration. For example,
we chose to test the impact on motivation after one
month instead of immediately after receiving feedback,
to give participants sufficient time to think about their
test results and to ask any questions. This may provide a
more accurate measure of the effects of test feedback
than the possibly transient ‘spur of the moment’ reac-
tions occurring immediately after receiving the genetic
test result. However, there are a number of limitations.
The study uses a young, healthy, well-educated sample,
which allows for investigating the effects of feedback but
limits generalizability of the results to the wider popula-
tion, particularly those with lower health literacy. Con-
trol over food choices in this study is limited due to theuniversity setting (the majority of students live in catered
halls). This may affect the ease with which weight gain
prevention can be achieved and results may differ in set-
tings where control over food intake is higher. Nonethe-
less, results from the current sample are of interest,
particularly because they provide an indication for the
effect of testing for prevention of unhealthy weight gain
in a population where weight gain is common. With this
study, we hope to provide a first indication of the poten-
tial benefits of inclusion of genetic testing into weight
management advice, laying the groundwork for future
research evaluating the clinical utility of genetic testing
for the prevention of ill health.
Trial status
Recruitment of participants is in progress.
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